eligibility_summary
Eligible: Adults (≥18) with histologically confirmed advanced breast cancer: hormone receptor–positive and/or HER2-positive/low, or triple-negative, included after ≥1 treatment cycle. Exclude: early breast cancer at enrollment, unwilling to provide informed consent or biological specimens, or lacking comprehensive clinical data.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT07066917 is an observational biomarker study in adults with locally advanced/metastatic breast cancer (HR+, HER2+/HER2-low, or TNBC) receiving innovative standard therapies. Interventions under study (no randomization): 1) Antibody–drug conjugates (biologic mAb-drug conjugates): trastuzumab deruxtecan (anti-HER2 linked to topoisomerase I inhibitor deruxtecan) and sacituzumab govitecan (anti-TROP2 linked to SN-38). MOA: bind HER2 or TROP2 on tumor cells, internalize, release cytotoxin causing DNA damage/apoptosis, possible bystander effect. 2) Immune checkpoint inhibitor (biologic mAb): pembrolizumab (anti-PD-1) blocks PD-1/PD-L1 to restore cytotoxic T-cell function. 3) PARP inhibitor (small molecule): olaparib inhibits PARP1/2, exploiting HRD/BRCA loss for synthetic lethality via failed DNA repair. Targets: HER2- or TROP2-expressing tumor cells, PD-1/PD-L1 immune checkpoint on T cells/tumor microenvironment, DNA damage response/HR pathway. Uses WES, ctDNA, digital pathology, radiomics to model response/resistance.